Zealand Pharma Presents Data On Glepaglutide at the 17th Congress Of the Intestinal Rehabilitation And Transplantation Association (Cirta)

Read Article

• Company presents three posters, including two on glepaglutide for the treatment of Short Bowel Syndrome (SBS)
• Data demonstrate potential dosing benefits of glepaglutide for patients with SBS

Copenhagen, DK and Boston, MA, U.S. June 29, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL)
(CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced it presented three posters at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA), which was held both virtually and in Auckland, New Zealand on June 30-July 2, 2021. The Company’s research presented at CIRTA 2021 featured multiple posters related to glepaglutide for the treatment of short bowel syndrome (SBS).

“We presented our research at CIRTA 2021,
including data on glepaglutide that suggest dose adjustment may not be necessary when treating SBS patients with renal impairment,” said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. “Renal impairment is a common comorbidity in SBS patients that often necessitates adjusting treatment regimen. However, we found no difference in the pharmacokinetic profile of glepaglutide in patients with severe renal impairment, or end stage renal disease, compared to healthy subjects, suggesting that dosage may not need to be adjusted for SBS patients with renal impairment.”

Poster Title: Glepaglutide pharmacokinetic profile after single subcutaneous injection in human subjects with varying degrees of renal function

Author: M Askjær Agersnap, K Sonne, K Mark Knudsen, S Wladyslaw

Poster Viewing Reception Date and Time: 30 June-2 July

Abstract Number: 113

Poster Title: Pharmacokinetics and pharmacodynamics of the long-acting GLP-2 analogue after once-weekly dosing in adult healthy subjects

Author: K Sonne, K Mark Knudsen, J Mosolff Mathiesen, G Koefoed Rasmussen, M Berner-Hansen Poster Viewing Reception Date and Time: 30 June-2 July

Abstract Number: 114

Poster Title: Relation between surgical procedures, chronic intestinal failure and dependency on parenteral support

Author: K Iyer, D Mercer, D Pfeffer, LB Zimmerman, M Berner-Hansen, M Mundi, DL Seidner Poster Viewing Reception Date and Time: 30 June-2 July

Abstract Number: 116

About Short Bowel Syndrome (SBS)

SBS is a complex chronic and severe condition associated with reduced or complete loss of
intestinal function. Many patients have to be connected to infusion lines and pumps every day, which pose significant restrictions on their ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and lifethreatening complications such as sepsis, blood
clots, liver damage and renal impairment.

About Glepaglutide

Glepaglutide is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome (SBS). Glepaglutide is being developed as a ready-to-use liquid product in an autoinjector desiged for convenient and easy subcutaneous administration. Zealand initiated the Phase 3 clinical program for Glepaglutide in October 2018.
The pivotal trial is a randomized, double-blind and placebo-controlled study, with both once- and twice-weekly dosing regimens. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the
discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and has received FDA approval for Zegalogue, (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealandinvented peptide investigational agents currently
in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S.
that includes key locations in New York, Boston, and Marlborough (MA).

For more information about Zealand’s business and activities, please visit:

Download Tables, Images & References